Cập nhật tin tức quốc tế

img
New Drug Combos Could Cut Heart Failure Mortality by 60%
New Drug Combos Could Cut Heart Failure Mortality by 60%

Optimized treatment can reduce the mortality risk for chronic heart failure (HF) by as much as 60%.

23/05/2025
img
Sotagliflozin Lowers A1c, Weight Even in Kidney Impairment
Sotagliflozin Lowers A1c, Weight Even in Kidney Impairment

Sotagliflozin (Inpefa): A Dual-Action Drug Offering Multiple Benefits for Patients with Type 2 Diabetes and Chronic Kidney Disease

19/05/2025
img
New Henipavirus Detected in Alabama
New Henipavirus Detected in Alabama

The discovery of the Camp Hill virus marks the first detection of a henipavirus in Alabama, North America

14/05/2025
img
WHO Updates Guidelines to Prevent Teen Pregnancy
WHO Updates Guidelines to Prevent Teen Pregnancy

World Health Organization (WHO) has updated its guidelines aimed at preventing adolescent pregnancy and mitigating its health impacts.

07/05/2025
img
FDA Approves New Monoclonal Antibody for Myasthenia Gravis
FDA Approves New Monoclonal Antibody for Myasthenia Gravis

FDA Approves New Monoclonal Antibody for Myasthenia Gravis

02/05/2025
img
Diet high in fiber, fermented foods could keep inflammatory diseases at bay
Diet high in fiber, fermented foods could keep inflammatory diseases at bay

Western Diet Increases Inflammation — Traditional African Diet May Protect Against Chronic Diseases

25/04/2025
img
Combination immunotherapy shrank a variety of metastatic gastrointestinal cancers
Combination immunotherapy shrank a variety of metastatic gastrointestinal cancers

New Combination Immunotherapy Shrinks Multiple Types of Metastatic Gastrointestinal Cancers

11/04/2025
img
Gut Dysbiosis in Irritable Bowel Syndrome
Gut Dysbiosis in Irritable Bowel Syndrome

The role of the gut microbiota in IBS has attracted significant interest from the scientific community.

05/04/2025
img
Oral GLP-1 Receptor Agonist Reduces CV Risk
Oral GLP-1 Receptor Agonist Reduces CV Risk

T2D who have cardiovascular disease, CKD, or both, the oral formulation of semaglutide GLP-1 receptor agonist, reduces the risk for major adverse cardiovascular events

31/03/2025